Despite having distinct benefits as the first and only once-daily, non-opioid IV analgesic, market conditions are not favorable for the introduction and commercialization of a new pain management product in the hospital market. As a result, Baudax Bio has formally discontinued the commercialization of ANJESO and the product is currently on hold due to these business conditions.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BXRX:
- Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
- Baudax Bio Soars on Promising Phase 2 Data for BX1000
- Baudax Bio announces interim analysis outcome of Phase II trial of BX1000
- Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
- Baudax Bio stops Anjeso sales, evaluating monetization approaches
